Evaxion Biotech A/S has announced promising new data on its personalized cancer vaccine, EVX-01, highlighting that 80% of the vaccine's targets elicited a tumor-specific immune response, significantly ...

The most common cancer in women — and one of the deadliest — may have finally met its match. Development of a breakthrough vaccine researchers say could eradicate breast cancer by 2030 wrapped up ...

GLSI-100 treatment in HER2-positive breast cancer patients shows increased immune responses, with visible skin reactions indicating efficacy. Both HLA-A*02 and non-HLA-A*02 patients exhibited immune ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

Cleveland Clinic researchers are presenting final Phase I data from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease ...

The aim of immunotherapy strategies is to leverage cells in the patient's own immune system to destroy tumor cells. Using a preclinical model, scientists from the Institut Pasteur and Inserm ...

PGV001 vaccine showed strong immune response and was well tolerated in a phase 1 trial with 13 patients across multiple cancer types. At five-year follow-up, six patients were alive, with three ...

Combination of Keytruda® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. Pancreatic cancer is of particular concern. The five-year survival rate ...